FDA Grants Vittoria Gene-Edited Cancer Therapy Fast-Track Status

Vittoria Biotherapeutics

PHILADELPHIA, PA — Vittoria Biotherapeutics has secured a U.S. Food and Drug Administration designation that could accelerate development and regulatory review of its experimental CAR-T cell therapy for patients with relapsed or treatment-resistant peripheral T-cell lymphoma, advancing the Philadelphia biotechnology company’s efforts to bring the treatment into pivotal clinical testing.

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Senza5 CART5, also known as VIPER-101, based on preliminary clinical evidence from an ongoing Phase 1 study.

The designation provides opportunities for earlier and more frequent discussions with FDA officials about clinical development, trial design and regulatory requirements. The therapy could also qualify for priority review or accelerated approval if it meets the applicable criteria.

Vittoria previously received Orphan Drug Designation for the treatment in July 2026, providing additional regulatory and financial incentives for developing a therapy targeting a rare disease.

READ:  Datavault AI Replaces CEO, Overhauls Executive Leadership

Together, the designations establish a regulatory framework for advancing Senza5 CART5 toward a potential approval application, although neither constitutes FDA approval or establishes that the treatment is safe and effective.

Senza5 CART5 is being developed for patients with relapsed or refractory CD5-positive peripheral T-cell lymphoma, a form of blood cancer that has returned after treatment or failed to respond to existing therapies.

The investigational treatment uses genetically modified T cells collected from a patient’s own immune system. Its design combines CD5-edited, CD5-directed CAR-T cells intended to attack cancer cells with a separate population of CD5-negative, CAR-negative T cells intended to support immune recovery.

The approach is designed to address challenges associated with targeting T-cell cancers, including the potential for engineered immune cells to attack one another.

Vittoria manufactures the treatment using a five-day process developed through its Senza5 platform.

READ:  Carpenter Technology Reshuffles Leadership to Support Growth

The FDA based its RMAT decision on clinical evidence from the Phase 1 VIPER-101 trial, which is evaluating the treatment in patients with relapsed or refractory CD5-positive peripheral T-cell lymphoma.

Additional results from the study, registered as NCT06420089, are scheduled for presentation December 14, 2026, during an oral session at the 68th American Society of Hematology Annual Meeting.

The upcoming presentation represents the next clinical milestone as Vittoria prepares to discuss pivotal-stage development with regulators.

“We look forward to working closely with FDA under the RMAT designation to advance Senza5 CART5 into a pivotal study for relapsed or refractory T-cell lymphoma,” said Nicholas A. Siciliano, Vittoria’s chief executive officer.

RMAT designation is available to certain regenerative medicine therapies intended to treat serious or life-threatening conditions when preliminary clinical evidence indicates they may address unmet medical needs.

READ:  Enviri Sets November 19 Investor Presentation in Dallas

The designation allows developers to engage with the FDA on development strategies that could support an expedited approval pathway.

Orphan Drug Designation separately provides incentives that can include tax credits for qualifying clinical trials, exemptions from certain regulatory fees and seven years of U.S. market exclusivity if the product receives approval for the designated indication.

Vittoria’s next development steps will center on the continuing VIPER-101 study and regulatory discussions concerning the design of a pivotal trial, with additional clinical findings expected at the December hematology meeting.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.